Read publication  

On Dec. 11, 2018, the United States Attorney's Office for the District of New Jersey submitted a statement of interest to a federal court, asking the court to rule on a specific question of law that implicates the scope of the materiality standard in False Claims Act jurisprudence: Whether a pharmaceutical company that violates the anti-kickback statute, or AKS, and causes a hospital to submit reimbursement claims for non-covered uses of a drug, can be held liable under the FCA if the federal government pays for the drug through a flat, bundled payment.

Published in Law 360 here on 28 January 2019.
Explore More Insight